Product Images Terazosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Terazosin Hydrochloride NDC 53808-0305 by State Of Florida Doh Central Pharmacy, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Terazosin Hcl 1 mg Caps - Terazosin 1mg(Teva)

Terazosin Hcl 1 mg Caps - Terazosin 1mg(Teva)

This is a medication label for Terazosin, a prescription drug, in the form of 1mg capsules. The label indicates a quantity of 30 capsules and a lot number of Kog20. The expiration date is listed as 0B3110. The pharmacy responsible for dispensing the medication is located in Tallahassee, FL, and the medication is for oral consumption.*

Terazosin Hcl 2 mg Caps - Terazosin 2mg(Teva)

Terazosin Hcl 2 mg Caps - Terazosin 2mg(Teva)

Chemical Structure - terazosin hydrochloride capsules 1

Chemical Structure - terazosin hydrochloride capsules 1

Figure 1 - terazosin hydrochloride capsules 2

Figure 1 - terazosin hydrochloride capsules 2

The text describes results from a study on a drug called Terazosin, showing the mean change in total symptom score and mean increase in peak flow rate from baseline for the drug compared to a placebo group. The data is presented in Figure 1 of Study 1 and indicates statistical significance with a p-value of less than 0.05. Baseline values can be found in a table mentioned in the text.*

Figure 2 - terazosin hydrochloride capsules 3

Figure 2 - terazosin hydrochloride capsules 3

This is a graph showing the mean change in total symptom score from baseline over a long-term, open-label, non-placebo controlled study that included 494 participants. The graph shows the mean change over time up to 30 months in patients with a certain condition. The mean baseline score was 10.7 and the study was able to show that there was a statistically significant improvement after 7 months of treatment.*

Figure 3 - terazosin hydrochloride capsules 4

Figure 3 - terazosin hydrochloride capsules 4

The text describes a figure, specifically Figure 3, that represents the mean change in Peak Flow Rate from Baseline in a Long-Term, Open-Label, Non-Placebo Controlled Study. The data is presented in a graph format and shows the mean change from baseline at months 0, 1, 2, 3, 12, 15, 18, 21, 24, 27, and 30. There is a statistically significant change (p<0.05) vs. baseline, and the mean baseline is 99. The context and purpose of the study are not provided in the text.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.